Description
Zolinza (Vorinostat) 100mg Online
Zolinza (Vorinostat) is used to treat cutaneous T-cell lymphoma (CTCL). CTCL is a type of cancer that affects certain white blood cells and causes lesions to develop on the skin. Zolinza interferes with the growth of the cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by Zolinza, other unwanted effects will also occur. Some of these may be serious and must be reported to your doctor. Some unwanted effects may not be serious but may cause concern. Some of the unwanted effects do not occur until months or years after the medicine is used.
Zolinza is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent, or recurrent disease on or following two systemic therapies. Zolinza (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that Zolinza also possesses some activity against recurrent glioblastoma multiforme, resulting in median overall survival of 5.7 months (compared to 4 – 4.4 months in earlier studies). Further brain tumor trials are planned in which Zolinza will be combined with other drugs.
